 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of renal[0m
[34mfailure?[0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or decrease the risk of renal[0m
[32mfailure?[0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"METOPROLOL TARTRATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m4[0m[31m%  [0m[1;31m<[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m23.2[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mBradycardia [0m[1;31m([0m[31mheart rate &lt;[0m[1;31m40[0m[31m beats/min[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m15.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m6.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m
[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> Second- or third-degree heart block  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4.7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m
[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m4[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m7[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr [0m[31mstyleCode[0m[31m=[0m[31m"Botrule"[0m[31m><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> First-degree heart block [0m[1;31m([0m[31mP-R [0m
[31m&#x2265;[0m[1;31m0.26[0m[31m sec[0m[1;31m)[0m[31m  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m5.3[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m1.9[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mstyleCode[0m[31m=[0m[31m"Lrule[0m[31m Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m> [0m
[31mHeart failure  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m27.5[0m[31m%  <[0m[31m/[0m[31mtd[0m[31m><td [0m[31malign[0m[31m=[0m[31m"center"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Rrule"[0m[31m [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m>[0m[1;31m29[0m[31m. METOPROLOL TARTRATE: adverse_reactions_table: [0m[1;31m6[0m[31m%  [0m
[31m<[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><[0m[31m/[0m[31mtbody[0m[31m><[0m[31m/[0m[31mtable[0m[31m>         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pediatric_use: Pediatric Use Safety and effectiveness in pediatric patients have not been established.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: precautions: PRECAUTIONS Risk of Anaphylactic Reactions While taking beta blockers, patients with a history of severe anaphylactic reaction to a variety of allergens may [0m
[31mbe more reactive to repeated challenge, either accidental, diagnostic, or therapeutic. Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. Information [0m
[31mfor Patients Advise patients to take metoprolol regularly and continuously, as directed, with or immediately following meals. If a dose should be missed, the patient should take only the next [0m
[31mscheduled dose [0m[1;31m([0m[31mwithout doubling it[0m[1;31m)[0m[31m. Patients should not discontinue metoprolol without consulting the physician. METOPROLOL TARTRATE: precautions: Advise patients [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m to avoid operating automobiles [0m
[31mand machinery or engaging in other tasks requiring alertness until the patientâ€™s response to therapy with metoprolol has been determined; [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m to contact the physician if any difficulty in breathing [0m
[31moccurs; [0m[1;31m([0m[1;31m3[0m[1;31m)[0m[31m to inform the physician or dentist before any type of surgery that he or she is taking metoprolol. Drug Interactions Catecholamine-depleting Drugs: Catecholamine-depleting drugs [0m[1;31m([0m[31me.g., [0m
[31mreserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a catecholamine depletor for evidence [0m
[31mof hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. METOPROLOL TARTRATE: precautions: In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. Calcium Channel Blockers: Concomitant administration[0m
[31mof a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative chronotropic and inotropic effects. CYP2D6 Inhibitors: [0m
[31mPotent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor metabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in[0m
[31mplasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol. METOPROLOL TARTRATE: drug_interactions: Known clinically significant potent inhibitors of CYP2D6 are [0m
[31mantidepressants such as fluvoxamine, fluoxetine, paroxetine, sertraline, bupropion, clomipramine, and desipramine; antipsychotics such as chlorpromazine, fluphenazine, haloperidol, and thioridazine; [0m
[31mantiarrhythmics such as quinidine or propafenone; antiretrovirals such as ritonavir; antihistamines such as diphenhydramine; antimalarials such as hydroxychloroquine or quinidine; antifungals such as [0m
[31mterbinafine. Hydralazine: Concomitant administration of hydralazine may inhibit presystemic metabolism of metoprolol leading to increased concentrations of metoprolol. METOPROLOL TARTRATE: [0m
[31mdrug_interactions: Alpha-adrenergic Agents: Antihypertensive effect of alpha-adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by [0m
[31mbeta-blockers including metoprolol. Beta-adrenergic blockers may also potentiate the postural hypotensive effect of the first dose of prazosin, probably by preventing reflex tachycardia. On the [0m
[31mcontrary, beta adrenergic blockers may also potentiate the hypertensive response to withdrawal of clonidine in patients receiving concomitant clonidine and beta-adrenergic blocker. If a patient is [0m
[31mtreated with clonidine and metoprolol concurrently, and clonidine treatment is to be discontinued, stop metoprolol several days before clonidine is withdrawn. Rebound hypertension that can follow [0m
[31mwithdrawal of clonidine may be increased in patients receiving concurrent beta-blocker treatment. METOPROLOL TARTRATE: drug_interactions: Drug Interactions Catecholamine-depleting Drugs: [0m
[31mCatecholamine-depleting drugs [0m[1;31m([0m[31me.g., reserpine[0m[1;31m)[0m[31m may have an additive effect when given with beta-blocking agents or monoamine oxidase [0m[1;31m([0m[31mMAO[0m[1;31m)[0m[31m inhibitors. Observe patients treated with metoprolol plus a [0m
[31mcatecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. In addition, possibly significant hypertension may theoretically [0m
[31moccur up to [0m[1;31m14[0m[31m days following discontinuation of the concomitant administration with an irreversible MAO inhibitor. Digitalis Glycosides and Beta-blockers: Both digitalis glycosides and beta-blockers [0m
[31mslow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Monitor heart rate and PR interval. METOPROLOL TARTRATE: drug_interactions: Calcium [0m
[31mChannel Blockers: Concomitant administration of a beta-adrenergic antagonist with a calcium channel blocker may produce an additive reduction in myocardial contractility because of negative [0m
[31mchronotropic and inotropic effects. CYP2D6 Inhibitors: Potent inhibitors of the CYP2D6 enzyme may increase the plasma concentration of metoprolol which would mimic the pharmacokinetics of CYP2D6 poor [0m
[31mmetabolizer [0m[1;31m([0m[31msee Pharmacokinetics section[0m[1;31m)[0m[31m. Increase in plasma concentrations of metoprolol would decrease the cardioselectivity of metoprolol.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: package_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: brand_name         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: product_ndc         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: openfda: spl_set_id         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patientâ€™s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: In patients who tolerate the full intravenous dose [0m[1;31m([0m[1;31m15[0m[31m mg[0m[1;31m)[0m[31m, initiate metoprolol tartrate tablets, [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours, [0m[1;31m15[0m[31m minutes after the [0m
[31mlast intravenous dose and continue for [0m[1;31m48[0m[31m hours. Thereafter, the maintenance dosage is [0m[1;31m100[0m[31m mg twice daily [0m[1;31m([0m[31msee Late Treatment below[0m[1;31m)[0m[31m. Start patients who appear not to tolerate the full intravenous [0m
[31mdose on metoprolol tartrate tablets either [0m[1;31m25[0m[31m mg or [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours [0m[1;31m([0m[31mdepending on the degree of intolerance[0m[1;31m)[0m[31m [0m[1;31m15[0m[31m minutes after the last intravenous dose or as soon as their clinical condition [0m
[31mallows. In patients with severe intolerance, discontinue metoprolol tartrate tablets [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. METOPROLOL TARTRATE: dosage_and_administration: Late Treatment Start patients with [0m
[31mcontraindications to treatment during the early phase of suspected or definite myocardial infarction, patients who appear not to tolerate the full early treatment, and patients in whom the physician [0m
[31mwishes to delay therapy for any other reason on metoprolol tartrate tablets, [0m[1;31m100[0m[31m mg twice daily, as soon as their clinical condition allows. Continue therapy for at least [0m[1;31m3[0m[31m months. Although the [0m
[31mefficacy of metoprolol beyond [0m[1;31m3[0m[31m months has not been conclusively established, data from studies with other beta-blockers suggest that treatment should be continued for [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m years. Special [0m
[31mPopulations Pediatric Patients : No pediatric studies have been performed. The safety and efficacy of metoprolol tartrate tablets in pediatric patients have not been established. Renal Impairment : No[0m
[31mdose adjustment of metoprolol tartrate tablets is required in patients with renal impairment. METOPROLOL TARTRATE: dosage_and_administration: Hepatic Impairment : Metoprolol blood levels are likely to[0m
[31mincrease substantially in patients with hepatic impairment. Therefore, metoprolol tartrate tablets should be initiated at low doses with cautious gradual dose titration according to clinical response.[0m
[31mGeriatric Patients [0m[1;31m([0m[1;31m>[0m[1;31m65[0m[31m years[0m[1;31m)[0m[31m : In general, use a low initial starting dose in elderly patients given their greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant [0m
[31mdisease or other drug therapy. Method of Administration For oral treatment, the tablets should be swallowed un-chewed with a glass of water. Metoprolol tartrate tablets should always be taken in [0m
[31mstandardized relation with meals. If the physician asks the patient to take metoprolol tartrate tablets either before breakfast or with breakfast, then the patient should continue taking metoprolol [0m
[31mwith the same schedule during the course of therapy.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pharmacokinetics: Pharmacokinetics Absorption The estimated oral bioavailability of immediate release metoprolol is about [0m[1;31m50[0m[31m% because of pre-systemic metabolism which is [0m
[31msaturable leading to non-proportionate increase in the exposure with increased dose. Distribution Metoprolol is extensively distributed with a reported volume of distribution of [0m[1;31m3.2[0m[31m to [0m[1;31m5.6[0m[31m L/kg. About[0m
[1;31m10[0m[31m% of metoprolol in plasma is bound to serum albumin. Metoprolol is known to cross the placenta and is found in breast milk. Metoprolol is also known to cross the blood brain barrier following oral [0m
[31madministration and CSF concentrations close to that observed in plasma have been reported. Metoprolol is not a significant P-glycoprotein substrate. Metabolism Metoprolol is primarily metabolized by [0m
[31mCYP2D6. METOPROLOL TARTRATE: pharmacokinetics: Metoprolol is a racemic mixture of R- and S- enantiomers, and when administered orally, it exhibits stereoselective metabolism that is dependent on [0m
[31moxidation phenotype. CYP2D6 is absent [0m[1;31m([0m[31mpoor metabolizers[0m[1;31m)[0m[31m in about [0m[1;31m8[0m[31m% of Caucasians and about [0m[1;31m2[0m[31m% of most other populations. Poor CYP2D6 metabolizers exhibit several-fold higher plasma concentrations [0m
[31mof metoprolol than extensive metabolizers with normal CYP2D6 activity thereby decreasing metoprololâ€™s cardioselectivity. Elimination Elimination of metoprolol is mainly by biotransformation in the [0m
[31mliver. The mean elimination half-life of metoprolol is [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m hours; in poor CYP2D6 metabolizers the half-life may be [0m[1;31m7[0m[31m to [0m[1;31m9[0m[31m hours. Approximately [0m[1;31m95[0m[31m% of the dose can be recovered in urine. METOPROLOL [0m
[31mTARTRATE: pharmacokinetics: In most subjects [0m[1;31m([0m[31mextensive metabolizers[0m[1;31m)[0m[31m, less than [0m[1;31m5[0m[31m% of an oral dose and less than [0m[1;31m10[0m[31m% of an intravenous dose are excreted as unchanged drug in the urine. In poor [0m
[31mmetabolizers, up to [0m[1;31m30[0m[31m% or [0m[1;31m40[0m[31m% of oral or intravenous doses, respectively, may be excreted unchanged; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity. [0m
[31mThe renal clearance of the stereo-isomers does not exhibit stereo-selectivity in renal excretion. Special Populations Geriatric Patients The geriatric population may show slightly higher plasma [0m
[31mconcentrations of metoprolol as a combined result of a decreased metabolism of the drug in elderly population and a decreased hepatic blood flow. However, this increase is not clinically significant [0m
[31mor therapeutically relevant. METOPROLOL TARTRATE: pharmacokinetics: Renal Impairment The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically [0m
[31msignificant degree from those in normal subjects. Hepatic Impairment Since the drug is primarily eliminated by hepatic metabolism, hepatic impairment may impact the pharmacokinetics of metoprolol. The[0m
[31melimination half-life of metoprolol is considerably prolonged, depending on severity [0m[1;31m([0m[31mup to [0m[1;31m7.2[0m[31m h[0m[1;31m)[0m[31m. Clinical Studies Hypertension In controlled clinical studies, metoprolol has been shown to be an [0m
[31meffective antihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics, at dosages of [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg daily. METOPROLOL TARTRATE: pharmacokinetics: In controlled, [0m
[31mcomparative, clinical studies, metoprolol has been shown to be as effective an antihypertensive agent as propranolol, methyldopa, and thiazide-type diuretics, to be equally effective in supine and [0m
[31mstanding positions. Angina Pectoris In controlled clinical trials, metoprolol, administered two or four times daily, has been shown to be an effective antianginal agent, reducing the number of angina [0m
[31mattacks and increasing exercise tolerance. The dosage used in these studies ranged from [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg daily. A controlled, comparative, clinical trial showed that metoprolol was indistinguishable from[0m
[31mpropranolol in the treatment of angina pectoris. METOPROLOL TARTRATE: pharmacokinetics: Myocardial Infarction In a large [0m[1;31m([0m[1;31m1[0m[31m,[0m[1;31m395[0m[31m patients randomized[0m[1;31m)[0m[31m, double-blind, placebo-controlled clinical study, [0m
[31mmetoprolol was shown to reduce [0m[1;31m3[0m[31m-month mortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. Patients were randomized and treated as soon as possible after their arrival in [0m
[31mthe hospital, once their clinical condition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of[0m
[31mshock, and/or more than minimal basal rales as signs of congestive heart failure. Initial treatment consisted of intravenous followed by oral administration of metoprolol or placebo, given in a [0m
[31mcoronary care or comparable unit. Oral maintenance therapy with metoprolol or placebo was then continued for [0m[1;31m3[0m[31m months. After this double-blind period, all patients were given metoprolol and followed [0m
[31mup to [0m[1;31m1[0m[31m year. METOPROLOL TARTRATE: pharmacokinetics: The median delay from the onset of symptoms to the initiation of therapy was [0m[1;31m8[0m[31m hours in both the metoprolol- and placebo-treatment groups. Among [0m
[31mpatients treated with metoprolol, there were comparable reductions in [0m[1;31m3[0m[31m-month mortality for those treated early [0m[1;31m([0m[31mâ‰¤[0m[1;31m8[0m[31m hours[0m[1;31m)[0m[31m and those in whom treatment was started later. Significant reductions in the [0m
[31mincidence of ventricular fibrillation and in chest pain following initial intravenous therapy were also observed with metoprolol and were independent of the interval between onset of symptoms and [0m
[31minitiation of therapy. In this study, patients treated with metoprolol received the drug both very early [0m[1;31m([0m[31mintra-venously[0m[1;31m)[0m[31m and during a subsequent [0m[1;31m3[0m[31m-month period, while placebo patients received no [0m
[31mbeta-blocker treatment for this period. The study thus was able to show a benefit from the overall metoprolol regimen but cannot separate the benefit of very early intravenous treatment from the [0m
[31mbenefit of later beta-blocker therapy. METOPROLOL TARTRATE: pharmacokinetics: Nonetheless, because the overall regimen showed a clear beneficial effect on survival without evidence of an early adverse[0m
[31meffect on survival, one acceptable dosage regimen is the precise regimen used in the trial. Because the specific benefit of very early treatment remains to be defined however, it is also reasonable to[0m
[31madminister the drug orally to patients at a later time as is recommended for certain other beta-blockers.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The provided extracts do not indicate that METOPROLOL TARTRATE increases or decreases the risk of renal failure. The adverse reactions table and other sections do not mention renal failure as [0m
[32ma known adverse effect or precaution.[0m

[32mSOURCE: METOPROLOL TARTRATE label[0m
[32mEXTRACT_START_END: METOPROLOL TARTRATE: adverse_reactions_table[0m[32m...[0m[1;32m29.6[0m[32m%[0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The provided extracts do not indicate that METOPROLOL [0m
[34mTARTRATE increases or decreases the risk of renal failure. The adverse reactions table and other sections do not mention renal failure as a known adverse effect or precaution.[0m

[34mSOURCE: METOPROLOL TARTRATE label[0m
[34mEXTRACT_START_END: METOPROLOL TARTRATE: adverse_reactions_table[0m[34m...[0m[1;34m29.6[0m[34m%[0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the METOPROLOL TARTRATE label does not indicate that the drug increases or decreases the risk of renal failure. The adverse reactions table and other sections do not [0m
[32mmention renal failure as a known adverse effect or precaution."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does METOPROLOL TARTRATE increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the METOPROLOL TARTRATE label does not indicate that the drug increases or decreases the risk of renal failure. The adverse reactions table and other sections do not [0m
[34mmention renal failure as a known adverse effect or precaution."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does METOPROLOL TARTRATE increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler responded that the METOPROLOL TARTRATE label does not indicate that the drug increases or decreases the risk of renal failure. The adverse reactions table and other sections do not [0m
[31mmention renal failure as a known adverse effect or precaution.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for METOPROLOL TARTRATE does not indicate that the drug increases or decreases the risk of renal failure. The adverse reactions table and other sections of the label do not mention renal[0m
[32mfailure as a known adverse effect or precaution. Therefore, based on the available FDA label data, it is not possible to determine if METOPROLOL TARTRATE has an effect on the risk of renal failure.[0m
